Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases

Next Previous
Trial Profile

A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary) ; Everolimus; Exemestane
  • Indications Adenocarcinoma; Advanced breast cancer; Bone metastases; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare

Most Recent Events

  • 01 Apr 2024 Results published in the Breast Cancer Research and Treatment
  • 04 Nov 2022 Status changed from active, no longer recruiting to completed.
  • 31 Aug 2022 Planned End Date changed from 30 Sep 2022 to 30 Oct 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top